New suction device aims to quickly clear lung clots in emergency setting

NCT ID NCT07685522

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This study tests a new device called the Vibrato Aspiration System, designed to remove blood clots from the lungs in people with acute pulmonary embolism (a sudden blockage in the lung artery). The trial includes up to 10 adults aged 18 to 75 who have had symptoms for 14 days or less and meet specific criteria. The goal is to see if the device is safe and can reduce the strain on the heart caused by the clot.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vibrato Aspiration System (mechanical thrombectomy device)
What this could lead to
If successful, this device could offer a less invasive way to quickly remove dangerous blood clots from the lungs, potentially reducing complications and improving recovery.
What could go wrong
This is a very early, small study (first in humans) with only 10 participants. The device may cause bleeding, vessel injury, or other serious side effects, and its effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects must meet all following general inclusion criteria: 1. Age ≥ 18 and ≤ 75 years. 2. Clinical signs, symptoms, and presentation consistent with acute PE; 3. PE symptom duration ≤ 14 days; 4. CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery) 5. RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined). 6. Systolic blood pressure ≥ 90 mmHg; 7. Stable heart rate \< 130 BPM prior to procedure; 8. Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment 9. Informed Consent Form signed 10. Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit Exclusion Criteria: Subjects must not meet any of the following general exclusion criteria: 1. Thrombolytic use within 30 days of baseline CT angiogram 2. Pulmonary hypertension with peak pulmonary artery pressure \> 70 mmHg by right heart catheterization (site determined) 3. Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg; 4. FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%; 5. Hematocrit \< 28%; 6. Platelets \< 100,000/ML; 7. Serum creatinine \> 1.8 mg/dL; 8. International normalized ratio (INR) \> 3; 9. Major trauma injury severity score (ISS) \> 15 within the past 14 days 10. Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators; 11. Cardiovascular or pulmonary surgery within last 7 days; 12. Actively progressing cancer requiring chemotherapy 13. Known bleeding diathesis or coagulation disorder; 14. Left bundle branch block; 15. History of severe or chronic pulmonary arterial hypertension; 16. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%; 17. History of uncompensated heart failure; 18. History of underlying lung disease that is oxygen dependent; 19. History of chest irradiation; 20. History of heparin-induced thrombocytopenia (HIT); 21. Patients who are under intubation 22. Any contraindication to systemic or therapeutic doses of heparin or anticoagulants; 23. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated; 24. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention; 25. Life expectancy of \< 90 days, as determined by Investigator; 26. Female who is pregnant or nursing; 27. Current participation in another investigational drug or device treatment study 28. History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days 29. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism acute are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Krakowski Szpital Specjalistyczny im. św. Jana Pawła II

    RECRUITING

    Krakow, Lesser Poland Voivodeship, 31-202, Poland

  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny

    NOT_YET_RECRUITING

    Poznan, Greater Poland Voivodeship, 61-848, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.